Kinases are a class of enzymes that facilitates phosphorylation, by transferring phosphate groups from high-energy donor molecules, such as ATP, to specific target molecules. A common group of kinases are the protein kinases, which act on specific proteins to phosphorylate them and alter their activity. Protein kinases are involved in a range of cell signaling and regulatory processes and play an important role in cell growth, metabolism, differentiation and apoptosis. Protein kinases have been associated with many diseases, including cancer, inflammatory diseases, cardiovascular diseases and neurological disorders. Therefore, targeting protein kinases has emerged as a promising therapeutic strategy for the treatment of related diseases.

Targetmol’s FDA-Approved Kinase Inhibitor Library contains 280 marketed drugs that target kinases. These kinases include Insulin/IGF Receptors、PI 3-Kinase、CaM Kinase II、JAK、PKA、CDK、JNK、PKC、CKI II、MAPK、RAF、EGFR、MEK、SAPK、GSK、MLCK、Src-family、IKK、PDGFR、VEGFR etc. FDA-Approved Kinase Inhibitor Library is a powerful tool for kinase drug development and related research.